Thirty-day mortality and thrombotic complications in patients treated with prothrombin complex concentrate for a factor Xa inhibitor–associated major bleeding event
| Reference . | Overall 30-d mortality, n . | Overall 30-d cumulative mortality, % . | Overall 30-d mortality rate (per 100 person-days) . | 30-d thrombotic events, n . | 30-d thrombotic events cumulative incidence, % . | 30-d thrombotic event rate (per 100 person-days) . | Hemostatic adequacy, n (%) . |
|---|---|---|---|---|---|---|---|
| Arachchillage8 | 27 | 34% | 1.4 | 3 | 3.8% | 0.2 | 59 (74%) |
| Majeed3 | 27 | 32% | 1.3 | 3 | 3.6% | 0.1 | 58 (69%) |
| Schenk4 | 3 | 23% | 0.9 | 2 | 15.4% | 0.6 | 10 (78%) |
| Schulman5 | 9 | 14% | 0.5 | 5 | 7.6% | 0.3 | 43 (65%) |
| Reference . | Overall 30-d mortality, n . | Overall 30-d cumulative mortality, % . | Overall 30-d mortality rate (per 100 person-days) . | 30-d thrombotic events, n . | 30-d thrombotic events cumulative incidence, % . | 30-d thrombotic event rate (per 100 person-days) . | Hemostatic adequacy, n (%) . |
|---|---|---|---|---|---|---|---|
| Arachchillage8 | 27 | 34% | 1.4 | 3 | 3.8% | 0.2 | 59 (74%) |
| Majeed3 | 27 | 32% | 1.3 | 3 | 3.6% | 0.1 | 58 (69%) |
| Schenk4 | 3 | 23% | 0.9 | 2 | 15.4% | 0.6 | 10 (78%) |
| Schulman5 | 9 | 14% | 0.5 | 5 | 7.6% | 0.3 | 43 (65%) |